Michael J Elliott, MBBS, PhD, FRACP
Chief Scientific Officer, Immunovant, Inc.
Dr Elliott is a physician scientist and drug developer and has served as Immunovant’s Chief Scientific Officer since August 2020. From December 2012 to August 2019, he served as Vice President, Immunology Scientific Innovation at Johnson & Johnson Innovation in Cambridge, MA, with responsibility for external collaborations and partnerships in Immunology. Prior to 2012, Dr. Elliott held various senior positions at Johnson & Johnson, including General Manager and Site Head, TransForm Pharmaceuticals, Inc. (a division of Johnson & Johnson) and Senior Vice President, Immunology, at Centocor, Inc. (a division of Johnson & Johnson), where he led the clinical development group. Dr Elliott earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a fellow of the Royal Australasian College of Physicians (FRACP). He currently serves on the board of Rhode Island Bio, a nonprofit life sciences industry organization, and is a member of the Rhode Island Science and Technology Advisory Committee.